FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 03:42:17 2024-05-31 pm EDT | ||
| 6.65 EUR | -12.27% |
|
| Current month | -47.64% | ||
| 1 month | -47.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 6.65 | -12.27% |
| 24-05-30 | 7.58 | +1.61% |
| 24-05-29 | 7.46 | +4.48% |
| 24-05-28 | 7.14 | +11.39% |
| 24-05-27 | 6.41 | -3.90% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 03:42 pm EDT
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2J2A |
| ISIN | DE000JK2J2A9 |
| Date issued | 2024-02-23 |
| Strike | 553.8 $ |
| Maturity | Unlimited |
| Parity | 14.12 : 1 |
| Emission price | 10.08 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.13 € |
|---|---|
| Lowest since issue | 6.41 € |
| Spread | 0.3 € |
| Spread % | 4.33% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
